A new horizon is opening up in regenerative medicine for small animal osteoarthritis.  Autologous stem cells have been used widely in recent years in the UK.  Elsewhere in the world allogeneic cells are also available.  The advent of a brand-new xenogeneic stem cell product may be a significant milestone in the discipline.

Helen Harrison BVSc CertAVP MRCVS discusses the use stem of cells for OA in general, and xenogeneic stem cells in particular.

Helen graduated with a veterinary degree from the University of Bristol in 2016 and completed her CertAVP in 2021. Helen worked in small animal practice until 2020, when she joined TVM-UK as a Veterinary Advisor. Helen now works as TVM’s Technical Manager for DogStem® and keeps her hand in with clinical work as a locum vet on weekends.  Outside of work, Helen volunteers for the BSAVA, enjoys rock climbing and long walks with her highly energetic Labrador!

Sponsor: Nupsala MSK Clinic www.nupsala-msk.co.uk

Podcast Content

In this podcast Helen discusses the following:

• the rationale for using stem cells in the management of osteoarthritis in veterinary patients.
• the actions of injected MSCs in the recipient joint.
• the current sources of mesenchymal stem cells for canine OA management.
• the differences between autologous-, allogeneic- and xenogeneic mesenchymal stem cells.
• the advantages and disadvantages of using xenogeneic equine umbilical cord MSCs compared to the other available MSCs?

This CPD content is suitable for: veterinary surgeons, veterinary nurses, veterinary physiotherapists, other professionals involved in osteoarthritis care.